Table 3 The clinical trials rendering MSCs-based therapy to accelerate wound healing and induce skin regeneration
Condition | Cell source | Results | References |
|---|---|---|---|
Cesarean section skin scars | UC | Fail to facilitate skin regeneration in cesarean section skin scars | [162] |
Ablative fractional laser (AFL) | AT | Skin regeneration by reduced MMP-1 and MMP-2 expression and also promoted collagen 1 expression | [165] |
Ablative fractional laser (AFL) | UC | Ameliorated wound healing and reduced post-treatment erythema by MSCs containing serum and cream | [166] |
Diabetic foot ulcers (DFU) | UC | Supporting greater and more stable wound repair | [167] |
Diabetic foot ulcers (DFU) | WJ | Verification of the safety and efficacy of acellular amniotic membrane seeded with WJ-SCs with a robust reduction in wound size | [168] |
Diabetic foot ulcers (DFU) | BM | Attenuated wound size and also improved vascularity of the dermis by combination therapy with fibroblasts on biodegradable collagen membrane accompanied with autologous BM-MSCs | [169] |
Bullosis diabeticorum (BD) | BM | Ameliorated clinical outcomes and prohibited lower limb amputation | [170] |
Epidermolysis bullosa (EB) | UC | Stimulation of M2 macrophage polarization and reducing mast cell infiltration in EB skin leading to diminished pain score and wound healing | [171] |
Chronic plantar ulcers in leprosy (CPUL) | AM | Stimulated wound healing by administration of MSCs-CM plus vitamins C or E | [163] |